For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

ARTICLES Summary Background We did a randomised controlled trial to assess the benefit of maintenance infliximab therapy in patients with active Crohn's disease who respond to a single infusion of infliximab.

[1]  G. Mullin,et al.  Lymphoma in inflammatory bowel disease , 2010, Cancer.

[2]  A. Zinsmeister,et al.  The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. , 2001, Gastroenterology.

[3]  S. Targan,et al.  Malignancy following remicadeTM therapy: Incidence and characteristics , 2001 .

[4]  S. Hanauer,et al.  Infliximab in Crohn's disease: first anniversary clinical experience , 2000, American Journal of Gastroenterology.

[5]  S. Nikolaus,et al.  Mechanisms in failure of infliximab for Crohn's disease , 2000, The Lancet.

[6]  H. Steinhart.  Maintenance therapy in Crohn's disease. , 2000, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[7]  T. Schaible.  Long term safety of infliximab. , 2000, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[8]  W. Sandborn,et al.  Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients , 2000, American Journal of Gastroenterology.

[9]  A. Kornbluth,et al.  Complete bowel obstruction following initial response to infliximab therapy for crohn's disease: A series of a newly described complication , 2000 .

[10]  E. Vasiliauskas,et al.  Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. , 1999, Gastroenterology.

[11]  G. Lichtenstein,et al.  Cancer risk in patients with inflammatory bowel disease. , 1999, Gastroenterology clinics of North America.

[12]  J. Hampe,et al.  Tumour necrosis factor α and interleukin 1β in relapse of Crohn's disease , 1999, The Lancet.

[13]  F. Breedveld,et al.  Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. , 1998, Arthritis and rheumatism.

[14]  P. Munkholm,et al.  Frequency of glucocorticoid resistance and dependency in Crohn's disease. , 1994, Gut.

[15]  J. Rochon,et al.  Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. , 1994, Gastroenterology.

[16]  B. Scallon,et al.  Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. , 1993, Molecular immunology.

[17]  S. Stephens,et al.  Tumour necrosis factor alpha in stool as a marker of intestinal inflammation , 1992, The Lancet.

[18]  H. Adami,et al.  Extracolonic malignancies in inflammatory bowel disease , 1991, Cancer.

[19]  A. Cooke,et al.  Tumour necrosis factor‐alpha and interferon‐gamma production measured at the single cell level in normal and inflamed human intestine , 1990, Clinical and experimental immunology.

[20]  V. Kindler,et al.  The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection , 1989, Cell.

[21]  F Kern,et al.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. , 1976, Gastroenterology.

[22]  R. Modigliani,et al.  Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. , 2000, The Cochrane database of systematic reviews.